CATHERINE MESSINGER: Open Payments
NPI 1811957350 · RICHMOND, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,512 in 86 payments from 15 companies in 2025. Trend: 2023 $53 · 2024 $301 · 2025 $1,512
Food & beverage: $1,440Education: $71
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $380 |
| Axsome Therapeutics, Inc. | 13 | $315 |
| Vanda Pharmaceuticals Inc. | 10 | $220 |
| Supernus Pharmaceuticals, Inc. | 12 | $120 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $86 |
| Teva Pharmaceuticals USA, Inc. | 2 | $86 |
| Alkermes, Inc. | 4 | $80 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
Products named: VRAYLAR, Auvelity, HETLIOZ, Qelbree, CAPLYTA, REXULTI, ARISTADA, XIFAXAN.
Industry payments across KY — which companies pay providers there.
